We rebuild overlooked assets into sharper clinical programs.
Revisioning Bio combines 505(b)(2) pathways, university research agreements, and in silico models to advance de-risked programs faster and with less wasted spend.
Operating Model
A concise framework for moving assets from underused to investable.
Regulatory Efficiency
We prioritize programs where 505(b)(2) can shorten the path, reduce duplication, and focus capital on the studies that change value.
- Existing human data
- Fewer avoidable studies
- Faster clinical positioning
Asset Repositioning
We look for shelved or underexploited assets that can be reframed with a stronger indication, cleaner biomarker strategy, or improved delivery thesis.
- Shelved compounds
- Sharper indication fit
- Higher-value milestones
Technology Strategy
We use external science selectively: university labs for fast data generation and AI models for better prioritization before expensive clinical spend.
Less overhead. Better decisions.
The goal is simple: start with better assets, test the highest-value questions first, and only advance programs that earn the next dollar.
Pipeline Snapshot
Representative programs shown at a high level.
| Program | Focus | Approach | Stage |
|---|---|---|---|
| RVB-101 | Neuroinflammation | 505(b)(2) repurposing strategy |
Clinical planning
|
| RVB-202 | Targeted Oncology | Shelved asset upgrade |
Preclinical buildout
|
| RVB-303 | Biofilm Control | Acoustic systems platform |
Feasibility
|
Open a conversation.
For licensing, research collaborations, or strategic discussions, reach out directly.